Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RGS12 | O14924 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11523096 | 0.80 | ALDH1A1 (0.42) | MAPTNOX4ALDH1A1RGS12EGFR | |
| SCHEMBL524509 | 0.78 | MCL1 (0.39) | MAPTNOX4ALDH1A1RGS12EGFR | |
| SCHEMBL11802986 | 0.78 | ALDH1A1 (0.36) | MAPTNOX4ALDH1A1RGS12EGFR | |
| SCHEMBL11549811 | 0.76 | PLK1 (0.48) | EGFRBCL2L1MCL1 | |
| SCHEMBL8856987 | 0.75 | GABRP (0.42) | MAPTNOX4ALDH1A1RGS12EGFR | |
| SCHEMBL9309430 | 0.75 | KDM4C (0.43) | MAPTNOX4ALDH1A1RGS12EGFR | |
| SCHEMBL5025350 | 0.75 | PLK1 (0.49) | MAPTBCL2L1MCL1 | |
| SCHEMBL1664315 | 0.73 | FNTA (0.53) | MAPTALDH1A1TDP1MEN1TSHR | |
| SCHEMBL1839262 | 0.73 | MAPT (0.54) | MAPTNOX4ALDH1A1RGS12EGFR | |
| Hydrochloric Acid SCHEMBL8785708 | 0.72 | MAPT (0.53) | MAPTNOX4ALDH1A1RGS12EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9314488-B2 | Cellular extracts | REGENICS AS (NO) | 2016-04-19 | — | — | US | claimed |
| US-8877253-B2 | Cellular extracts | REGENICS AS (NO) | 2014-11-04 | — | — | US | claimed |
| US-20120121673-A1 | Topical Compositions Comprising Inorganic Particulates And An Alkoxylated Diphenylacrylate Compound | SUSAK MILANKA (CA) | 2012-05-17 | — | — | US | claimed |
| CN-101415399-B | Skin lightening agents and compositions | UNILEVER NV | 2011-11-16 | — | — | CN | claimed |
| US-12458687-B2 | Wound debridement systems | REGENICS AS (NO) | 2025-11-04 | — | — | US | disclosed |
| EP-3866818-B1 | USE OF FISH EGG CELLULAR EXTRACTT FOR WOUND HEALING | REGENICS AS (NO) | 2025-07-23 | — | — | EP | disclosed |
| EP-3454826-B1 | WHIPPED GEL FORMULATIONS | FORMULATED SOLUTIONS LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220370503-A1 | METHODS AND DEVICES FOR THE PRODUCTION AND DELIVERY OF BENEFICIAL FACTORS FROM STEM CELLS | AELAN CELL TECHNOLOGIES, INC. | 2022-11-24 | — | — | US | disclosed |
| US-20220347273-A1 | WOUND DEBRIDEMENT SYSTEMS | REGENICS AS (NO) | 2022-11-03 | — | — | US | disclosed |
| US-20220288095-A1 | SIALIC ACID FOR USE IN THE TREATMENT OF PSORIASIS | LIFESCIENCE AS (NO) | 2022-09-15 | — | — | US | disclosed |
| EP-4003365-A1 | SIALIC ACID FOR USE IN THE TREATMENT OF PSORIASIS | Lifescience AS (NO) | 2022-06-01 | — | — | EP | disclosed |
| EP-3993765-A1 | WOUND DEBRIDEMENT SYSTEMS | Regenics AS (NO) | 2022-05-11 | — | — | EP | disclosed |
| EP-1778882-A2 | NOVEL BACTERIA AND PHARMACEUTICALLY ACTIVE PRODUCTS OBTAINED THEREFROM | State of Israel, Department of Agriculture, Kimron Veterinary Institute (IL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006011137-A2 | NOVEL BACTERIA AND PHARMACEUTICALLY ACTIVE PRODUCTS OBTAINED THEREFROM | STATE OF ISRAEL, DEPARTMENT OF AGRICULTURE, KIMRON VETERINARY INSTITUTE (IL) | 2006-02-02 | — | — | WO | disclosed |
| US-20050107302-A1 | Applying formulation containing ovalbumin containing a growth factor selected from epidermal growth factor, transforming growth factor alpha, fibroblast growth factors, phenoxyethanol, triethanolamine, carbomer for scar prevention | DAWSON MONICA E (US) | 2005-05-19 | — | — | US | disclosed |
| US-20030176345-A1 | Wound healing composition and method for use thereof | DAWSON MONICA E (US) | 2003-09-18 | — | — | US | disclosed |
| US-6541447-B1 | Mixture of ovalbumin, phenoxyethanol, carbomer and triethanolamine | B & M HEALTHCARE TECHNOLOGIES, INC. | 2003-04-01 | — | — | US | disclosed |
| US-6514744-B2 | Skin moisturizer | KIBUN FOOD CHEMIFA CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-5766575-A | APPLYING A PHENOLIC DERIVATIVE | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5460832-A | Skin cosmetic having an egg white enzyme hydrolysate with hyaluronic acid synthesis promoting activity | TAIYO KAGAKU CO., LTD. (JP) | 1995-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121673-A1 | Topical Compositions Comprising Inorganic Particulates And An Alkoxylated Diphenylacrylate Compound | CUTA, ALAD, AAAS | MAPT 131/4885NOX4 1694/4885ALDH1A1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.